DALLAS, Sept. 16, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring medical device company China Medical Technologies Inc. (Nasdaq:CMED). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on China Medical Technologies Inc. (Nasdaq:CMED) should be of particular interest to other medical device companies: Quidel Corp. (Nasdaq:QDEL), Meridian Bioscience Inc. (Nasdaq:VIVO), Inverness Medical Innovations Inc. (NYSE:IMA) and Bio-Rad Laboratories Inc. (NYSE:BIO).

It is available at: http://www.stockpreacher.com/n/CMED

China Medical Technologies Inc. (CMED), a medical device company, engages in the development, manufacture, commercialization and sale of medical devices and supplies in the People's Republic of China. It offers in-vitro diagnostics (IVD) products, which utilize enhanced chemiluminescence immunoassay (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders through laboratory evaluation and analysis of blood, urine, or other body fluids and system.

In the report, the analyst notes:

"The Company has operated the ECLIA business for more than five years. Over the last year, the number of competitors has increased; the price differentiation has become narrower and until recently, the Company's products price was just slightly lower than the international players pricing. Meanwhile, the Company's domestic competitors' products pricing was roughly about 50% lower than CMED's price. During the past few months, the Company lost about 15% of its major distributors to competitors. As a result, in September 2009, CMED adopted a final strategy and reduced prices by about 30%, which made its pricing still about 30% to 35% lower than the international players pricing after the adjustment.

"For its FISH business, CMED has already established direct relationships with 400 hospital customers; the Company is still planning to penetrate its FISH probes to remaining tier 1 large hospitals in China, but at a slower pace. CMED is currently focusing on strengthening relationships with the existing hospital and promoting the clinical benefits of FISH probes among relevant departments of its hospital customers."

To read the entire report visit: http://www.stockpreacher.com/n/CMED

See what investors are saying about these stocks at: http://www.stockhideout.com/

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT:  StockPreacher.com
          Jeff Bishop
          (469)-252-3505
          press@beaconequity.com